Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
Who exactly is “people like me”?
Stop making assumptions. Particularly when my comments directly contradict them.
You’re reading things in my comments that aren’t there.
And by the way, GPL-1s aren’t some sudden fix. Yes it helps with the appetite and hunger.
But that comes with other baggage, like needing to monitor for side effects, finding the proper dosage (and keeping on it.)
It’s certainly not a viable solution at the scale that’s currently necessary. Even so, I’m not seeing anyone here saying traditional weight loss isn’t hard- and I’m certainly not.